Featured Research

from universities, journals, and other organizations

Cellular feast or famine: How cells decide whether they have enough fat

Date:
April 5, 2011
Source:
Sanford-Burnham Medical Research Institute
Summary:
Not all cholesterol is bad. Every cell requires it for growth -- they either have to get cholesterol somewhere or they die. In a new study, researchers found that a protein sensor known to balance cholesterol sources can also access a previously under-appreciated cellular fat storage depot.

Not all cholesterol is bad. Every cell requires it for growth -- they either have to get cholesterol somewhere or they die. In a new study published April 6 in the journal Cell Metabolism, researchers from Sanford-Burnham Medical Research Institute (Sanford-Burnham) and their collaborators found that a protein sensor known to balance cholesterol sources can also access a previously under-appreciated cellular fat storage depot.

The sensor, called sterol regulatory element-binding protein 2 (SREBP-2), monitors cellular cholesterol levels and responds to low levels by switching on genes that allow the cell to either 1) take up more from the bloodstream or 2) manufacture more from cholesterol building blocks inside the cell. Now, Sanford-Burnham's Timothy Osborne, Ph.D., and his team have uncovered a third cholesterol source also controlled by SREBP-2: fat droplets stored inside the cell itself.

"We were searching the mouse liver cell genome to find DNA sequences specifically bound by SREBP-2," said Dr. Osborne, director of the Metabolic Signaling and Disease Program in Sanford-Burnham's Diabetes and Obesity Research Center. "First we were surprised that SREBP-2 binds very close to the genes it regulates -- that's not typical. Second, we were surprised to find that in addition to genes related to fat metabolism and cholesterol balance, SREBP-2 also binds and activates genes responsible for autophagy."

When times get tough, autophagy is the cell's way of recycling its own old or damaged parts. Dr. Osborne and his team found that SREBP-2 uses autophagy as a way to liberate cholesterol stored by some cells in fat droplets. (Here they looked at liver cells, which have large fat droplets. In contrast, other cell types -- neurons, for example -- aren't known to store fat.) When cholesterol was limited, autophagy genes were switched on and fat droplets were joined by autophagosomes (bags of enzymes the cell deploys for self-destruction). As a result, more cholesterol was available for cells to repair membranes, burn as energy or drive other life-sustaining processes.

The role of SREBP-2 in autophagy and cholesterol generation was confirmed using cells engineered to lack the protein. Facing cholesterol shortage, SREBP-2-deficient cells were unable to switch on autophagy genes and autophagosomes did not form as readily as they did in normal cells.

"This study identified a key regulatory step that determines how cells decide whether they have sufficient stored fat, or whether new fat needs to be produced internal cellular sources or obtained from the environment," Dr. Osborne said. "Genetic or environmental conditions that interfere with this regulatory step could lead to diseases such as obesity or cardiovascular disease."

This study was funded by the National Heart, Lung and Blood Institute and the National Library of Medicine, both parts of the National Institutes of Health, and the National Science Foundation.


Story Source:

The above story is based on materials provided by Sanford-Burnham Medical Research Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Young-Kyo Seo, Tae-Il Jeon, Hansook Kim Chong, Jacob Biesinger, Xiaohui Xie, Timothy F. Osborne. Genome-wide Localization of SREBP-2 in Hepatic Chromatin Predicts a Role in Autophagy. Cell Metabolism, 2011; 13 (4): 367-375 DOI: 10.1016/j.cmet.2011.03.005

Cite This Page:

Sanford-Burnham Medical Research Institute. "Cellular feast or famine: How cells decide whether they have enough fat." ScienceDaily. ScienceDaily, 5 April 2011. <www.sciencedaily.com/releases/2011/04/110405122330.htm>.
Sanford-Burnham Medical Research Institute. (2011, April 5). Cellular feast or famine: How cells decide whether they have enough fat. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/04/110405122330.htm
Sanford-Burnham Medical Research Institute. "Cellular feast or famine: How cells decide whether they have enough fat." ScienceDaily. www.sciencedaily.com/releases/2011/04/110405122330.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins